Earnings Call · Q2 FY2024·2024-08-15

Q2 21EPS n/a·Rev n/aQ1 21EPS n/a·Rev n/aQ4 20EPS n/a·Rev n/aQ2 20EPS n/a·Rev n/a⚠ consensus missing

NRX Pharmaceuticals, Inc. NRXPW

Matthew Duffy — Chief Commercial Officer

Dr. Jonathan Javitt — Chief Medical Officer

Stephen Willard — CEO

Richard Narido — CFO

−14.3%1d on move date−14.5% vs SPY3d−14.3%5d+17.9%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NRXPW calls or request research access.

More NRXPW calls Browse calls Request research access